Bikunin Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Induction in Macrophages
- 1 November 2004
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 11 (6) , 1140-1147
- https://doi.org/10.1128/cdli.11.6.1140-1147.2004
Abstract
Bikunin, a Kunitz-type protease inhibitor, exhibits anti-inflammatory activity in protection against cancer and inflammation. To investigate the molecular mechanism of this inhibition, we analyzed the effect of bikunin on tumor necrosis factor alpha (TNF-α) production in human peripheral mononuclear cells stimulated by lipopolysaccharide (LPS), an inflammatory inducer. Here, we show the following results. (i) LPS induced TNF-α expression in time- and dose-dependent manners through phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase pathways. (ii) Bikunin inhibits LPS-induced up-regulation of TNF-α protein expression in a dose-dependent manner, reaching 60% inhibition at the highest doses of bikunin tested (5.0 μM). (iii) Inhibition by bikunin of TNF-α induction correlates with the suppressive capacity of ERK1/2, JNK, and p38 signaling pathways, implicating repressions of at least three different signals in the inhibition. (iv) Bikunin blocks the induction of TNF-α target molecules interleukin-1β (IL-1β) and IL-6 proteins. (v) Bikunin is functional in vivo, and this glycoprotein blocks systemic TNF-α release in mice challenged with LPS. (vi) Finally, bikunin can prevent LPS-induced lethality. In conclusion, bikunin significantly inhibits LPS-induced TNF-α production, suggesting a mechanism of anti-inflammation by bikunin through control of cytokine induction during inflammation. Bikunin might be a candidate for the treatment of inflammation, including septic shock.Keywords
This publication has 39 references indexed in Scilit:
- Bikunin plus paclitaxel markedly reduces tumor burden and ascites in mouse model of ovarian cancerInternational Journal of Cancer, 2004
- Therapeutic efficacy of once‐daily oral administration of a Kunitz‐type protease inhibitor, bikunin, in a mouse model and in human cancerCancer, 2004
- Correlation between Mortality and the Levels of Inter‐Alpha Inhibitors in the Plasma of Patients with Severe SepsisThe Journal of Infectious Diseases, 2003
- Bikunin Target Genes in Ovarian Cancer Cells Identified by Microarray AnalysisJournal of Biological Chemistry, 2003
- Chemoprotection by Phenolic AntioxidantsPublished by Elsevier ,2002
- Intravenous Ulinastatin Therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric PatientsInternational Archives of Allergy and Immunology, 2002
- Suppression of Urokinase Expression and Invasiveness by Urinary Trypsin Inhibitor Is Mediated through Inhibition of Protein Kinase C- and MEK/ERK/c-Jun-dependent Signaling PathwaysPublished by Elsevier ,2001
- Editorial: Inflammation, Tumor Necrosis Factor, and ToxicologyEnvironmental Health Perspectives, 1998
- Ulinastatin, a human trypsin inhibitor, inhibits endotoxin-induced thromboxane B sub 2 production in human monocytesCritical Care Medicine, 1997
- Cytokines and the immune responseBiotherapy, 1996